



(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2018/045056

(22) International Filing Date:
02 August 2018 (02.08.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/541,024 03 August 2017 (03.08.2017) US
62/667,388 04 May 2018 (04.05.2018) US

(71) Applicant: ALECTOR LLC [US/US]; 151 Oyster Point
Boulevard, Suite 300, South San Francisco, California
94080 (US).

(72) Inventors: CULP, Patricia. LAM, Helen. ROSEN-
THAL, Arnon. LEE, Seung-Joo. NIELSON, Nels P. PE-
JCHAL, Robert.

(74) Agent: ZHOU, Jie et al.; Morrison & Foerster LLP, 425
Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))